Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,500.95 -0.70 -0.00%
S&P 500 1,878.44 3.05 0.16%
NASDAQ 4,147.59 20.63 0.50%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Upcoming Results from Clinical Trials - Research Report on Gilead Sciences, Celgene Corporation, Sinovac Biotech, NPS



 Upcoming Results from Clinical Trials - Research Report on Gilead Sciences,
    Celgene Corporation, Sinovac Biotech, NPS Pharmaceuticals and ZIOPHARM
                                   Oncology

PR Newswire

NEW YORK, March 18, 2013

NEW YORK, March 18, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Sinovac
Biotech Ltd. (NASDAQ: SVA), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

Gilead Sciences recently presented results from a new study indicating that
its angina drug Ranexa was able to reduce the frequency of chest pain of
patients with diabetes. Ranexa is already approved to treat patients with
angina, a type of chest pain associated with heart disease, but the new study
was done to test if the drug can be used for diabetics, who can experience
more complications as opposed to other drug patients. According to Dr. Mikhail
Kosiborod, the drug may also have a glucose lowering effect aside from being
an anti-anginal drug. If this effect is confirmed in future studies, patients
with diabetes and angina may receive dual benefits from the drug. Ranexa has
been providing substantial gains for Gilead, contributing $373 million in
sales in 2012. If approved for as a drug for patients with diabetes, the drug
may be able to further boost sales. The Full Research Report on Gilead
Sciences, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/9696_GILD]

--

Celgene Corporation Research Report

The Bank of America reiterated its Buy rating on Celgene and increased its
price target from $113 to $127 following the results of a commissioned
statistical analysis that the firm completed regarding Celgene's MM-020 study
for its myeloma drug, Revlimid. The study will expand the indication of the
drug from relapsed/refractory myeloma to a broader range of patients who are
newly diagnosed with multiple myeloma. Bank of America has reversed its
bearish stance on the outcome of the study but maintains the crucial effect of
the results on the company's shares. Looking forward, Celgene expects Revlimid
net product sales to increase 10 percent year-over-year to a range of $4,100
to $4200 million. The Full Research Report on Celgene Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.WallStSource.com/r/full_research_report/7541_CELG]

--

Sinovac Biotech Ltd. Research Report

Sinovac's shares jumped as much as 60 percent in early trading as the
China-based company presented late-stage trials of its experimental vaccine
for hand, mouth and foot disease (HFMD). The study met its end goal of
preventing infection in infants between 6 to 35 months. The results showed
that 95.4 percent of vaccinated subjects showed immune response. According to
Aegis Capital analyst Raghuram Selvaraju the vaccine is likely to get approval
from Chinese regulators by the first quarter of 2013 and may be launched in
the middle of 2014. Cases of HFMD total at around 2 million in China and the
vaccination program could reach at least 10 million people. This shows how
much potential gains the vaccines can provide for the company. The Full
Research Report on Sinovac Biotech Ltd. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WallStSource.com/r/full_research_report/846e_SVA]

--

NPS Pharmaceuticals, Inc. Research Report

NPS Pharmaceuticals recently launched its newly approved product, Gattex, the
first and only long-term treatment for adult short bowel syndrome. To expand
its potential further, NPS Pharmaceuticals is currently conducting a new
study, which will expand the uses of the drug for children. Aside from this,
NPS Pharmaceuticals is on its way to submit its Biologics License Application
in the second half of 2013 for Natpara, a replacement therapy for
hypoparathyroidism. The final study will be conducted this month for Natpara
with results expected in the second quarter of 2013. With a newly launched
product and another product underway, NPS Pharmaceuticals may be on its way to
achieve strong profitability. The company's Sensipar royalty agreement with
Amgen also generates $63 million in annual cash flows, helping the company
stay afoot. The Full Research Report on NPS Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.WallStSource.com/r/full_research_report/4519_NPSP]

--

ZIOPHARM Oncology, Inc. Research Report

ZIOPHARM Oncology recently initiated Phase 2 Study of Ad-RTS IL-12 in
combination with palifosfamide to treat patients with advanced breast cancer.
According to ZIOPHARM CEO Jonathan Lewis, "The study has exciting potential,
both for this difficult-to-treat indication and for our synthetic biology
platform… we believe the combination of Ad-RTS IL-12 and palifosfamide has the
potential to be quite impactful in breast cancer." Furthermore, Ziopharm has
told investors to expect phase II study results for its sarcoma drug
palifosfamide in the last week of March. As the deadline looms, many may
expect the company to gain plenty of interest from analysts and investors with
its promising pipeline and prospects. The Full Research Report on ZIOPHARM
Oncology, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/71e2_ZIOP]

--

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Joe Thomas
Email: press@wallstsource.com
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement